Skip to main content
ADMA BIOLOGICS, INC. logo

ADMA BIOLOGICS, INC. — Investor Relations & Filings

Ticker · ADMA ISIN · US0008991046 US Manufacturing
Filings indexed 962 across all filing types
Latest filing 2025-01-02 Board/Management Inform…
Country US United States of America
Listing US ADMA

About ADMA BIOLOGICS, INC.

https://www.admabiologics.com/

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company that develops, manufactures, and commercializes specialty plasma-derived biologics. The company's portfolio features FDA-approved immune globulin (Ig) products for the treatment of immune-compromised patients and individuals at risk for certain infections. ADMA Biologics operates a vertically integrated manufacturing process for its specialty biologic products and utilizes a patented immunotechnology platform, which includes a proprietary microneutralization assay to measure neutralizing antibody levels in plasma. The company also offers contract manufacturing capabilities.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated December 30, 2024, reporting the appointment of a new director to the Board of Directors of ADMA Biologics, Inc. The key content is the announcement of a board member change, including biographical details and compensation information. There are no financial statements or detailed financial performance data. The document fits the description of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2025-01-02 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The key content is the announcement of repayment of $30 million from a senior secured term loan facility, which is a financing activity. The document includes a press release about this repayment. There are no detailed financial statements or comprehensive financial analysis present, so it is not an Annual Report, Interim Report, or Earnings Release. The focus on repayment of a loan facility aligns with capital or financing updates. Therefore, the document is best classified as a Capital/Financing Update (CAP). The document length is 3075 characters, which is short but contains substantive information about financing activity, not just a report publication announcement or regulatory filing. Confidence is high due to clear content and form type.
2024-12-20 English
FORM 4
Director's Dealing
2024-12-03 English
FORM 4
Director's Dealing
2024-11-23 English
Director's Dealing 2024
Director's Dealing
2024-11-23 English
Regulatory Filings 2024
Regulatory Filings
2024-11-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.